Bradley Merrill Thompson Quoted in Article, “Would a Fixed-Term FDA Commissioner Help Industry? Maybe, Maybe Not”

The Gray Sheet

Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the Washington, DC, office, was quoted in an article titled "Would a Fixed-Term FDA Commissioner Help Industry? Maybe, Maybe Not."

Following is an excerpt:

FDA needs a commissioner position less prone to turnover every four years, said John Sheets, senior VP of corporate research at Boston Scientific.

For device firms, "the course change changes [our] destination," Sheets said during a panel discussion with other industry executives at the Cleveland Clinic's Medical Innovations Summit Oct. 3.

Experts say having a fixed six-year term would probably attract a different type of FDA commissioner — one who might bring a needed change in leadership style.
"It appeals to a different kind of person — a person who wants to get in and make operational changes and be there long enough to see those changes through," said Thompson, who counsels device and drug companies on FDA matters.

"It isn't just taking the current environment and adding or making it six years," he said.